Cisplatin for Dogs: What This Powerful Chemotherapy Drug Does and What to Expect

Cisplatin is one of the heavy hitters of veterinary cancer care — a potent, injectable chemotherapy drug that can do real good against some of the toughest cancers dogs face. Like many of the medications used in veterinary oncology, it was first developed for people and later adapted for animals. Decades of veterinary studies have since mapped out both what it can accomplish and the risks that come with it, and dogs have benefited enormously from that crossover between human and veterinary medicine.

It's a serious drug, though, with serious side effects, so it's always given under the close supervision of a veterinary oncologist. Here's a plain-language guide to what cisplatin is, the cancers it's used for, how your dog receives it, and the safety steps that matter most.

What Cisplatin Is

Cisplatin is a platinum-based chemotherapy drug — the "cis-platin" name comes from the platinum atom at the center of the molecule. It's given by injection, not as a pill. Because it was developed for humans, there's no veterinary-labeled version; vets use the human product (brand names Platinol® and Platinol-AQ®, along with generic forms) "off-label," which is standard and accepted practice in animal cancer care.

An important warning: cisplatin must never be given to cats. It causes fatal lung damage in felines even at low doses. This is strictly a canine (and other-species) medication — it is not a household drug that can be shared between pets.

How Cisplatin Works

Cisplatin belongs to a class of drugs called alkylating agents. Once inside a cell, it binds to and damages DNA, jamming up the cell's ability to copy its genetic material, read it (RNA transcription), and build the proteins it needs. A cell that can't do those things can't divide — and since cancer cells are constantly dividing, they're especially vulnerable. The catch is that cisplatin doesn't only target cancer cells; it affects any fast-dividing tissue, which is the source of most of its side effects.

Which Cancers Cisplatin Is Used For

Cisplatin is versatile, and the right choice always comes down to a risk-versus-benefit judgment by your oncologist. Here's where the veterinary evidence has pointed:

Osteosarcoma (bone cancer) is where cisplatin made its name in dogs. It has long been a backbone of treatment after limb amputation, helping delay the spread of this aggressive cancer. A 2000 pilot study of 16 dogs found that pairing cisplatin with the chemotherapy drug doxorubicin lengthened the disease-free interval — the stretch of time before the cancer returned. The trade-off surfaced in later studies (2003 and 2008): a notable share of dogs had significant toxic effects from that combination, which led researchers to rethink dosing and, in many practices, to shift toward better-tolerated platinum drugs like carboplatin.

Squamous cell carcinoma and oral melanoma. When combined with the anti-inflammatory drug piroxicam, cisplatin showed measurable anti-tumor activity against oral squamous cell carcinoma and oral melanoma in dogs.

Mesothelioma and carcinomatosis. For these cancers, which spread along the lining of a body cavity, cisplatin can be delivered directly into the affected chest or abdominal cavity (called intracavitary treatment), where it has helped bring the disease under control.

Soft tissue sarcomas. In a study of 62 dogs, surgeons removed lower-grade soft tissue sarcomas and placed cisplatin-impregnated beads directly into the surgical site. This local approach produced minimal toxicity and some benefit — a way to concentrate the drug where it's needed while sparing the rest of the body.

Transitional cell carcinoma (bladder cancer). This is a case where the evidence steered away from cisplatin. A 2007 study combining cisplatin with piroxicam for bladder TCC found that the drug's toxic effects outweighed its benefit, so other options are generally preferred here.

Germinal (germ) cell tumors. These are uncommon in dogs, but cisplatin has been used for them historically.

How Your Dog Receives Cisplatin

Cisplatin can be given in several ways depending on the cancer: into a vein (intravenous), directly into a body cavity (intracavitary), straight into a tumor (intralesional), or via slow-release beads implanted at a surgical site.

When it's given intravenously, your dog will need to be hospitalized for several hours. That's not a formality — cisplatin is hard on the kidneys, and the hospital stay allows a careful protocol of intravenous fluids (called diuresis) before, during, and after the drug to flush the kidneys and protect them. Anti-nausea medication is typically given alongside it. The exact dose, route, and schedule are all decided by your veterinary oncologist based on the cancer type and how your dog responds.

Because cisplatin is administered and stored at the clinic, there's no at-home dosing to manage. If you have to miss or reschedule an appointment, just coordinate with your oncology team — they'll adjust the plan.

Side Effects to Know About

Cisplatin's power comes with a real side-effect profile, which is exactly why it's used so carefully and why bloodwork is checked before and during treatment to watch organ function. Potential effects include:

• Kidney damage (the headline risk) — the reason for all the IV fluids and monitoring
• Gastrointestinal upset — nausea, vomiting, and reduced appetite
• Hearing damage (ototoxicity) — cisplatin can harm the inner ear
• Nerve damage (neurotoxicity)
• Bone marrow suppression — lower blood-cell counts, which can raise the risk of infection and bleeding
• Other possible effects — coat changes, elevated liver enzymes, seizures, electrolyte imbalances, and loss of appetite

Anti-nausea medication and fluid therapy during treatment help blunt several of these. Some clinicians have also suggested antioxidants such as vitamins A and E and glutathione to guard against hearing damage — but never start any supplement without clearing it with your dog's oncologist first, since some supplements can interfere with chemotherapy.

Drugs and Conditions That Don't Mix With Cisplatin

Dogs with pre-existing kidney disease or bone marrow suppression usually aren't good candidates for cisplatin. Several medications also need to be avoided or used cautiously, generally because they pile onto cisplatin's effects on the kidneys, hearing, or bone marrow. These include other bone-marrow-suppressing drugs, NSAIDs (non-steroidal anti-inflammatories), aminoglycoside antibiotics, the antibiotic polymyxin B, the diuretic furosemide, vaccines, certain other cancer drugs (such as tigilanol tiglate/Stelfonta and Laverdia), and drugs that affect heart rhythm (acepromazine, amiodarone, cisapride, quinidine, and sotalol). As a rule, anything that can damage the kidneys or hearing should be kept off the table during cisplatin treatment. This is why your oncologist needs a full list of every medication and supplement your dog takes.

Safety at Home: Protecting Your Family After Treatment

Here's reassuring news: with a few sensible precautions, your dog is perfectly safe to be around the rest of the family after chemotherapy. The drug leaves the body through waste, so the precautions center on handling that waste for a few days.

• For about 3 to 5 days after each treatment (and on treatment day), avoid direct contact with your dog's urine, feces, vomit, and blood.
• Wear gloves to clean up any waste, seal it in a bag, and then double-bag it before putting it in the trash.
• Clean any soiled areas with a bleach solution.
• Keep waste away from other pets and people — for example, take your dog out in your own yard rather than to public areas while the drug clears.
• If cisplatin was injected directly into a tumor, avoid contact with the injection site as well.

These steps are simple, and they're temporary — they don't mean your dog is "radioactive" or that you should keep your distance from your companion when they need you most.

When to Call Your Oncologist Right Away

Watch your dog closely after each treatment, and reach out promptly if you notice signs that may point to bone marrow suppression or another serious effect:

• Bleeding or unusual bruising
• Fever
• Shortness of breath or labored breathing
• Marked lethargy, repeated vomiting, or refusal to eat

When in doubt, call. With a drug as potent as cisplatin, it's always better to check in early than to wait.

The Bottom Line

Cisplatin is a powerful, well-studied tool that has genuinely extended and improved the lives of many dogs — especially those with osteosarcoma. It isn't a gentle drug, and it demands careful patient selection, hospital-based administration with kidney protection, and attentive monitoring. But in the right dog, with the right cancer, and the right oncology team, it can be a valuable part of the plan. Talk through the risks and benefits openly with your veterinary oncologist so you know what to expect and can make the choice that's right for your dog.

This article is for educational purposes and reflects the current state of veterinary research; it isn't a substitute for individualized veterinary advice. Always consult your veterinarian or a veterinary oncologist before starting, stopping, or changing any treatment for your dog. Cisplatin is never appropriate for cats.

References

Bacon, N. J., Ehrhart, N. P., Dernell, W. S., Lafferty, M., & Withrow, S. J. (2008). Use of alternating administration of carboplatin and doxorubicin in dogs with microscopic metastases after amputation for appendicular osteosarcoma: 50 cases (1999–2006). Journal of the American Veterinary Medical Association, 232(10), 1504–1510. https://doi.org/10.2460/javma.232.10.1504

Barabas, K., Milner, R., Lurie, D., & Adin, C. (2008). Cisplatin: A review of toxicities and therapeutic applications. Veterinary and Comparative Oncology, 6(1), 1–18. https://doi.org/10.1111/j.1476-5829.2007.00142.x

Bergman, N. S., Urie, B. K., Pardo, A. D., & Newman, R. G. (2016). Evaluation of local toxic effects and outcomes for dogs undergoing marginal tumor excision with intralesional cisplatin-impregnated bead placement for treatment of soft tissue sarcomas: 62 cases (2009–2012). Journal of the American Veterinary Medical Association, 248(10), 1148–1156. https://doi.org/10.2460/javma.248.10.1148

Boria, P. A., Murry, D. J., Bennett, P. F., Glickman, N. W., Snyder, P. W., Merkel, B. L., Schlittler, D. L., & Knapp, D. W. (2004). Evaluation of cisplatin combined with piroxicam for the treatment of oral malignant melanoma and oral squamous cell carcinoma in dogs. Journal of the American Veterinary Medical Association, 224(3), 388–394. https://doi.org/10.2460/javma.2004.224.388

Chun, R., Kurzman, I. D., Couto, C. G., Klausner, J., Henry, C., & MacEwen, E. G. (2000). Cisplatin and doxorubicin combination chemotherapy for the treatment of canine osteosarcoma: A pilot study. Journal of Veterinary Internal Medicine, 14(5), 495–498. https://doi.org/10.1892/0891-6640(2000)014<0495:CADCCF>2.3.CO;2

DeRegis, C. J., Moore, A. S., Rand, W. M., & Berg, J. (2003). Cisplatin and doxorubicin toxicosis in dogs with osteosarcoma. Journal of Veterinary Internal Medicine, 17(5), 668–673. https://doi.org/10.1111/j.1939-1676.2003.tb02498.x

Greene, S. A., Lucroy, M. D., Greenberg, C. B., Bonney, P. L., & Knapp, D. W. (2007). Evaluation of cisplatin administered with piroxicam in dogs with transitional cell carcinoma of the urinary bladder. Journal of the American Veterinary Medical Association, 231(7), 1056–1060. https://doi.org/10.2460/javma.231.7.1056

Moore, A. S., Kirk, C., & Cardona, A. (1991). Intracavitary cisplatin chemotherapy experience with six dogs. Journal of Veterinary Internal Medicine, 5(4), 227–231. https://doi.org/10.1111/j.1939-1676.1991.tb00953.x

Plumb, D. C. (2022). Cisplatin. In Plumb's veterinary drugs. https://app.plumbs.com/